title: Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy.
authors.affiliation: Matthew P. Goetz, Mayo Clinic, Rochester, MN; Mark Ratain, The University of Chicago, Chicago, IL; and James N. Ingle, Mayo Clinic, Rochester, MN.
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Goetz
authors.affiliation: Matthew P. Goetz, Mayo Clinic, Rochester, MN; Mark Ratain, The University of Chicago, Chicago, IL; and James N. Ingle, Mayo Clinic, Rochester, MN.
authors.forename: Mark
authors.initials: M
authors.lastname: Ratain
authors.affiliation: Matthew P. Goetz, Mayo Clinic, Rochester, MN; Mark Ratain, The University of Chicago, Chicago, IL; and James N. Ingle, Mayo Clinic, Rochester, MN.
authors.forename: James N
authors.initials: JN
authors.lastname: Ingle
mesh_terms: D018931:Antineoplastic Agents, Hormonal; D001943:Breast Neoplasms; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D005838:Genotype; D006801:Humans; D011110:Polymorphism, Genetic; D013629:Tamoxifen
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6